Engineered light-activated anion channel proteins and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10478499-B2
Application number	US-201816057639-A
Country	US
Kind code	B2
Filing date	Aug 7, 2018
Priority date	Mar 28, 2014
Publication date	Nov 19, 2019
Grant date	Nov 19, 2019

Abstract

Aspects of the disclosure include compositions, devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering light-responsive polypeptides, or nucleic acids encoding same, to target cells. The subject compositions and systems include light-activated polypeptides, nucleic acids comprising nucleotide sequences encoding these polypeptides, as well as expression systems that facilitate expression of these polypeptides in target cells. Also provided are methods of using the subject devices and systems to optogenetically manipulate action potentials in target cells, e.g., to treat a neurological or psychiatric condition in a human or animal subject.

First claim

What is claimed is:

1. A light-activated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:23, wherein the polypeptide functions as a light-activated anion channel, and wherein the polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid substitutions selected from A59S, E90S, E101S, E123S, Q117K, H134R, V242K, T246N and N258Q, relative to the amino acid sequence of ChR2 (SEQ ID NO:79).

2. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:23.

3. The polypeptide of claim 1 , comprising an endoplasmic reticulum (ER) export polypeptide.

4. The polypeptide of claim 3 , wherein the ER export polypeptide comprises the amino acid sequence FXYENE (SEQ ID NO:92), where X is any amino acid.

5. The polypeptide of claim 1 , comprising a membrane trafficking polypeptide.

6. The polypeptide of claim 5 , wherein the membrane trafficking polypeptide comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:83).

7. The light-activated polypeptide of claim 5 , wherein the polypeptide further comprises a C128T, C128A, or C128S substitution, relative to the amino acid sequence of ChR2 (SEQ ID NO:79).

8. The light-activated polypeptide of claim 1 , wherein the polypeptide further comprises a D156A or a D156N substitution, relative to the amino acid sequence of ChR2 (SEQ ID NO:79).

9. A nucleic acid comprising a nucleotide sequence encoding a light-activated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:23, wherein the polypeptide functions as a light-activated anion channel, and wherein the polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid substitutions selected from A59S, E90S, E101S, E123S, Q117K, H134R, V242K, T246N and N258Q, relative to the amino acid sequence of ChR2 (SEQ ID NO:79).

10. A recombinant expression vector comprising the nucleic acid of claim 9 .

11. A pharmaceutical composition comprising:
a) the recombinant expression vector of claim 10 ; and
b) a pharmaceutically acceptable carrier.

12. A cell comprising the nucleic acid of claim 9 .

13. A cell comprising the recombinant expression vector of claim 10 .

14. A system for modulating the membrane potential of a cell, the system comprising:
a) the recombinant vector of claim 10 ; and
b) a device configured to illuminate a target location with light.

15. The system of claim 14 , wherein the device is configured to illuminate the target location with light having a wavelength ranging from about 350 nm to about 750 nm, or from about 450 nm to about 500 nm.

16. The system of claim 14 , wherein the device is configured to:
a) constantly illuminate the target location with light;
b) illuminate the target location with pulses of light;
c) modulate the wavelength and/or the intensity of the light;
d) modulate the frequency and/or the duration of the pulses of light; or
e) illuminate the target location in response to a user input.

17. The system of claim 14 , wherein the device is configured to illuminate the target location in response to a user input, and wherein the user input comprises: the wavelength of light, the intensity of light, the duration of a light pulse, the frequency of a light pulse, and/or the target location.

18. The system of claim 14 , wherein the device is adapted to be implanted in a subject.

19. The system of claim 14 , wherein the target location is: a cell, a portion of a cell, a plurality of cells, a bundle of nerve fibers, a neuromuscular junction, a central nervous system (CNS) tissue, a peripheral nervous system (PNS) tissue, or an anatomical region.

20. A method for modulating the membrane potential of a cell in response to light, the method comprising exposing a cell to light of an activating wavelength, wherein the cell is genetically modified with the recombinant vector of claim 10 .

21. The method of claim 20 , wherein the cell is a neuron.

Assignees

• Univ Leland Stanford Junior
• The Board Of The Trustees Of The Leland Stanford Junior Univ

Inventors

• Deisseroth Karl A
• Lee Soo Yeun
• Ramakrishnan Charu
• Berndt Andre

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61N5/0622

  Optical stimulation for exciting neural tissue · CPC title

• C07K14/47

  from mammals · CPC title

• A61K41/0042 Primary

  Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion · CPC title

• C07K2319/01

  containing a localisation/targetting motif · CPC title